{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=34", "query": { "condition": "Non-Hodgkin's Lymphoma (disorder)", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 2150, "total_pages": 215, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin%27s+Lymphoma+%28disorder%29&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T00:48:38.903Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00897325", "title": "Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 811, "start_date": "2006-09-25", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 119 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897325" }, { "nct_id": "NCT01186458", "title": "Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Velcade", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2010-10", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2016-10-24", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 11, "location_summary": "Bloomington, Indiana • Fort Wayne, Indiana • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Bloomington", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186458" }, { "nct_id": "NCT00080925", "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2004-02", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080925" }, { "nct_id": "NCT00575068", "title": "Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "IDEC-114", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2002-01", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2012-06-08", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 4, "location_summary": "Tucson, Arizona • Rochester, Minnesota • Buffalo, New York + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00575068" }, { "nct_id": "NCT04231747", "title": "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma Non-Hodgkin", "Agressive Lymphoma", "Diffuse-large B-cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "CC-97540", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-05-21", "completion_date": "2024-02-01", "has_results": false, "last_update_posted_date": "2024-05-20", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04231747" }, { "nct_id": "NCT03132584", "title": "Cyclophosphamide and Alemtuzumab In Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin Lymphoma", "High-grade B-cell Lymphoma", "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 3, "start_date": "2017-07-30", "completion_date": "2018-01-30", "has_results": false, "last_update_posted_date": "2019-01-14", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03132584" }, { "nct_id": "NCT01000753", "title": "Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adult Immunoblastic Lymphoma", "Central Nervous System Non-Hodgkin Lymphoma", "Childhood Immunoblastic Lymphoma", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3 Follicular Lymphoma", "Lymphoproliferative Disorder", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Non-Hodgkin Lymphoma", "Primary Cutaneous B-Cell Non-Hodgkin Lymphoma", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 174, "start_date": "2005-05-30", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 119, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 93 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01000753" }, { "nct_id": "NCT03038672", "title": "Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ALK-Positive Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "EBV-Positive Mucocutaneous Ulcer", "HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Intravascular Large B-Cell Lymphoma", "Large B-Cell Lymphoma With 11q Aberration", "Large B-Cell Lymphoma With IRF4 Rearrangement", "Plasmablastic Lymphoma", "Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System", "Primary Effusion Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Gray-Zone Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent Lymphomatoid Granulomatosis", "Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Gray-Zone Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Varlilumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2018-12-21", "completion_date": "2026-10-24", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03038672" }, { "nct_id": "NCT05784441", "title": "A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory B Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "JNJ-90009530", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2023-11-06", "completion_date": "2040-01-03", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 7, "location_summary": "Iowa City, Iowa • Lexington, Kentucky • Rochester, Minnesota + 4 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05784441" }, { "nct_id": "NCT05107856", "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "B-cell Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myelomonocytic Leukemia", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndromes", "Myeloproliferative Neoplasm", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "PRT1419", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2022-03-22", "completion_date": "2024-01-19", "has_results": false, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-10-17T00:48:38.903Z", "location_count": 9, "location_summary": "Orange City, Florida • Orlando, Florida • Bethesda, Maryland + 6 more", "locations": [ { "city": "Orange City", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Brick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107856" } ] }